NASDAQ:QURE went some really unusual trading options last Monday when traders bought close to 618 stocks on the put option. This was an increase of around 758% when compared to the 72 put options’ value. There have been several reports issued on NASDAQ:QURE by research firms. Stifel Nicolaus did lower the objective price for this firm from $86 to $78, along with a ‘buy’ rating. This move was thought to be a valuation call. Credit Suisse Group also brought forth a ‘buy’ rating, along with a target price of $76 in a 31st July note. ValuEngine, too dropped NASDAQ:QURE from a ‘buy’, to a ‘hold’ in an October 1st rating.
Two of the analysts working on this firm have already rated the entire stock with a ‘sell’, while three of them have given it a ‘hold’. Ten of the analysts have brought forth a ‘buy’ rating, while one of them has given it a ‘strong buy’. The company at this moment has a price target of $74.08, along with a rating of ‘Buy’.
The quarterly earnings for NASDAQ:QURE was posted on Thursday, with the biotechnology company reporting an EPS of $0.96 for this quarter, which missed the consensus estimate. The revenue of this company in that period was $1.54 million, which was well below the analysts’ expectations of $17.87 million.
uniQure (NASDAQ:QURE) Company Profile
NASDAQ:QURE is a gene therapy company which has engaged itself in the commercialization and development of treatments for those patients who have been suffering from any genetic diseases in the Netherlands.
The post NASDAQ:QURE’s Put Options Bought By Investors in High Volume first appeared on Armenian American Reporter.